Cover Image

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test

Abstract Background The expression of PD-L1 in the immune microenvironment can guide the application of immunosuppressants. In order to monitor the immune status of the body, repeated biopsies have to be taken. Our research aims to find new and convenient means to evaluate this indicator. Methods Ei...

Full description

Saved in:

Bibliographic Details
Main Authors:	Keyu Yuan (Author), Jiangping Wu (Author), Yanjie Zhao (Author), Shuzhen Lyu (Author), Quan Zhou (Author), Feng Shi (Author), Yanping Li (Author), Qingkun Song (Author)
Format:	Book
Published:	BMC, 2022-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
by: Monika Walankiewicz, et al.
Published: (2018)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021)

Meningiomas and the tumor microenvironment: expression of PD-L1 and expression of PD-L1 and interferon-gamma in the prognosis
by: Gunter Gerson, et al.

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019)

Profile of PD-1 and PD-L1 mRNA Expression in Peripheral Blood of Nasopharyngeal Carcinoma
by: Muhammad Al Al Azhar, et al.
Published: (2020)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
by: Matyas Meggyes, et al.
Published: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022)

Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients with Psoriasis
by: Selma Emre, et al.
Published: (2023)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
by: Vishakha Singh, et al.
Published: (2021)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
by: van Wijk Femke, et al.
Published: (2011)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
by: Zsófia Király, et al.
Published: (2022)

Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
by: Manuel A Silva, et al.
Published: (2020)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018)

PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021)

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023)

The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024)

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules
by: Marialuigia Fantacuzzi, et al.
Published: (2024)

BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells
by: Katia R. M. Leite, et al.
Published: (2022)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
by: Yuqian Feng, et al.
Published: (2021)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018)

Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
Published: (2020)

Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs
by: Preslav Vasilev, et al.
Published: (2024)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019)

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
by: Ryunosuke Hoshi, et al.
Published: (2024)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
by: Yanhua Bai, et al.
Published: (2017)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia
by: Laura Jimbu, et al.
Published: (2021)